TY - JOUR
T1 - Risk factors for fatal cardiac complications after allogeneic hematopoietic cell transplantation
T2 - Japanese Society for Transplantation and Cellular Therapy transplant complications working group
AU - Yanagisawa, Ryu
AU - Tamaki, Masaharu
AU - Tanoshima, Reo
AU - Misaki, Yukiko
AU - Uchida, Naoyuki
AU - Koi, Satoshi
AU - Tanaka, Takashi
AU - Ozawa, Yukiyasu
AU - Matsuo, Yayoi
AU - Tanaka, Masatsugu
AU - Ikegame, Kazuhiro
AU - Katayama, Yuta
AU - Matsuoka, Ken ichi
AU - Ara, Takahide
AU - Kanda, Yoshinobu
AU - Matsumoto, Kimikazu
AU - Fukuda, Takahiro
AU - Atsuta, Yoshiko
AU - Kato, Motohiro
AU - Nakasone, Hideki
N1 - Publisher Copyright:
© 2022 John Wiley & Sons Ltd.
PY - 2022
Y1 - 2022
N2 - Fatal cardiac complications can occur from the early to late phases after hematopoietic cell transplantation (HCT). Herein, the Japanese transplant registry database was used to retrospectively analyze health records of 33,791 allogeneic HCT recipients to elucidate the pathogenesis and risk factors involved. Overall, 527 patients died of cardiac complications at a median of 130 (range 0–3924) days after HCT. The cumulative incidence of fatal cardiac complications was 1.2% (95% confidence interval [CI]: 1.0–1.3) and 1.6% (95% CI: 1.5–1.8) at 1 and 5 years after HCT, respectively. Fatal cardiovascular events were significantly associated with an HCT-specific comorbidity index (HCT-CI) score of ≥1 specific to the three cardiovascular items, lower performance status, conditioning regimen cyclophosphamide dose of >120 mg/kg, and female sex. Cardiovascular death risk within 60 days after HCT was associated with the type of conditioning regimen, presence of bacterial or fungal infections at HCT, and number of blood transfusions. Contrastingly, late cardiovascular death beyond 1 year after HCT was associated with female sex and older age. Lower performance status and positive cardiovascular disease-related HCT-CI were risk factors for cardiac complications in all phases after HCT. Systematic follow-up may be necessary according to the patients' risk factors and conditions.
AB - Fatal cardiac complications can occur from the early to late phases after hematopoietic cell transplantation (HCT). Herein, the Japanese transplant registry database was used to retrospectively analyze health records of 33,791 allogeneic HCT recipients to elucidate the pathogenesis and risk factors involved. Overall, 527 patients died of cardiac complications at a median of 130 (range 0–3924) days after HCT. The cumulative incidence of fatal cardiac complications was 1.2% (95% confidence interval [CI]: 1.0–1.3) and 1.6% (95% CI: 1.5–1.8) at 1 and 5 years after HCT, respectively. Fatal cardiovascular events were significantly associated with an HCT-specific comorbidity index (HCT-CI) score of ≥1 specific to the three cardiovascular items, lower performance status, conditioning regimen cyclophosphamide dose of >120 mg/kg, and female sex. Cardiovascular death risk within 60 days after HCT was associated with the type of conditioning regimen, presence of bacterial or fungal infections at HCT, and number of blood transfusions. Contrastingly, late cardiovascular death beyond 1 year after HCT was associated with female sex and older age. Lower performance status and positive cardiovascular disease-related HCT-CI were risk factors for cardiac complications in all phases after HCT. Systematic follow-up may be necessary according to the patients' risk factors and conditions.
KW - cardiomyopathy
KW - cardiovascular disease
KW - congestive heart failure
KW - cyclophosphamide
KW - HCT-CI
UR - http://www.scopus.com/inward/record.url?scp=85142760968&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142760968&partnerID=8YFLogxK
U2 - 10.1002/hon.3101
DO - 10.1002/hon.3101
M3 - Article
C2 - 36385399
AN - SCOPUS:85142760968
SN - 0278-0232
JO - Hematological Oncology
JF - Hematological Oncology
ER -